COMMUNIQUÉS West-GlobeNewswire

Context Therapeutics Reports Full Year 2025 Operating and Financial Results
23/03/2026
Phase 1a interim data for ongoing trial of CTIM-76 (CLDN6 x CD3) expected in June 2026 Phase 1a interim data for ongoing trial of CT-95 (MSLN x CD3) expected in September 2026 Cash and cash equivalents of $66.0 million [...]
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
23/03/2026
BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, in November 2025 and on March 23, 2026, [...]
Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026
23/03/2026
Monday, March 30: Phase 1 data on TNX-4800 (long-acting anti-Borrelia OspA human monoclonal antibody) for the seasonal prevention of Lyme disease Wednesday, April 1: Animal and in vitro studies on TNX-801 (horsepox, [...]
Inventiva annonce la publication et la présentation de ses résultats financiers annuels 2025
23/03/2026
Daix (France), New York ( États-Unis ), le 23 mars 2026 – Inventiva (Euronext Paris et Nasdaq : IVA ) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement d’une thérapie orale [...]
Inventiva Schedules the Publication and Presentation of its 2025 Full-Year Financial Results
23/03/2026
Daix (France), New York (United States), March 23, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral [...]
Globus Medical Announces Board Departure
23/03/2026
AUDUBON, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Globus Medical , Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced that John A. DeFord, PhD, a Director of Globus Medical Inc., notified the [...]
Outlook Therapeutics Announces Proposed Public Offering
23/03/2026
ISELIN, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, [...]
AFB Research Reveals Attitudes Toward and Reach of AI with Focus on Disability
23/03/2026
WASHINGTON, March 23, 2026 (GLOBE NEWSWIRE) -- The American Foundation for the Blind today released a new study on the experiences and perceptions of people with and without disabilities using AI. The report — The AI [...]
Galapagos and Gilead in Advanced Discussions to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases
23/03/2026
Galapagos intends to enter into a strategic collaboration with Gilead following Gilead's acquisition of Ouro Medicines New partnership structure would achieve meaningfully improved financial terms and flexibility for [...]
Resolutions from the Annual General Meeting 2026
23/03/2026
Today, the Annual General Meeting of Novonesis (Novozymes A/S) was conducted. The following resolutions were made: Approval of the audited Annual Report for 2025 Approval of distribution of profit with payment of an [...]
Stryker announces Annual Meeting of Shareholders
23/03/2026
Portage, Michigan, March 23, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced its 2026 Annual Meeting of Shareholders is scheduled as follows: Wednesday, May 6, 2026 – 12:00 p.m. Eastern Time The Meeting will be [...]
MEDVi Quad Prescription Access Updated as Telehealth ED Treatment Demand Rises in 2026
23/03/2026
Los Angeles, March 23, 2026 (GLOBE NEWSWIRE) -- As demand for telehealth erectile dysfunction treatment access continues to grow in 2026, updated disclosures for MEDVi Quad , a prescription-only ED treatment, have been [...]
NMDP(SM) Advances Cell Therapy Research in Clinical Practice and Patient Outcomes at EBMT 2026
23/03/2026
Real-world data advances new insights into donor selection, benchmarks for patient infection prevention and comparative outcomes in a modern post-transplant cyclophosphamide (PTCy) era MINNEAPOLIS, March 23, 2026 (GLOBE [...]
OSE Immunotherapeutics invitée à présenter lors des prochaines conférences investisseurs
23/03/2026
Nantes, France, 23 mars 2026 – 18h00 CET – OSE Immunotherapeutics SA (ISIN : FR0012127173 ; Mnemo : OSE) , une société de biotechnologie au stade clinique développant des thérapies first-in-class en immuno-oncologie et [...]
OSE Immunotherapeutics to Present at Upcoming Investor Conferences
23/03/2026
Nantes, France, March 23, 2026 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) , a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno- [...]
AdipoPharma Enters Clinic with First-in-Class Therapy Targeting Type 2 diabetes with the potential to maintain muscle mass
23/03/2026
This novel whole-body insulin-sensitizing approach is designed to address insulin resistance independent of weight loss PITTSBURGH, March 23, 2026 (GLOBE NEWSWIRE) -- As GLP-1 therapies reshape obesity care, one biotech [...]
Umoja Biopharma Appoints Dr. Marcela Maus and Dr. Athena Countouriotis to Board of Directors
23/03/2026
SEATTLE, March 23, 2026 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a clinical-stage biotechnology company committed to delivering innovative and potentially curative immunotherapies for patients with cancer and [...]
Children’s National launches Division of AI Research to lead the future of artificial intelligence in pediatric medicine
23/03/2026
New division will build infrastructure to bring trustworthy, clinically grounded AI to help care for kids Washington, DC, March 23, 2026 (GLOBE NEWSWIRE) -- Children’s National Hospital has launched the Division of AI [...]
Checkerspot Announces Breakthrough, using Microalgae to Produce Palmitoleic Acid Oil at Scale, Opening a New Pathway to Omega-7s
23/03/2026
Peer-reviewed study in the Journal Fermentation details Checkerspot achieving up to 58% palmitoleic acid content, establishing a scalable, sustainable Omega-7 alternative to macadamia nuts, sea buckthorn, and fish- [...]

Pages